Search By:
Products
Injury
Topic
Company
Industry
Solvay Pharmaceuticals might have wrongfully marketed its hormone replacement therapy drug Estratest as working to treat hot flashes when no FDA approval existed.
Investigation Source
- Nationwide
Investigation Scope
Category Information
Investigation Topics
- Misrepresentation
- Off label promotion of drug
Product or Service
- Estratest
Injury Type
- Monetary Loss
Investigation Details
Investigation and pending class action lawsuit against Solvay Pharmaceuticals claiming that the drug maker has engaged in false and illegal marketing of Estratest, a hormone replacement therapy drug the company has been marketing without FDA approval.
The class action lawsuit alleges Solvay Pharmaceuticals marketing materials falsely stated that the hormone replacement therapy drug Estratest worked to treat hot flashes, something the FDA recently began questioning, and implied the drug was approved by the FDA. Although Solvay applied for approval in 1981, the FDA never approved Estratest for its marketed use.
Do not change medications without first consulting your doctor.
The class action lawsuit alleges Solvay Pharmaceuticals marketing materials falsely stated that the hormone replacement therapy drug Estratest worked to treat hot flashes, something the FDA recently began questioning, and implied the drug was approved by the FDA. Although Solvay applied for approval in 1981, the FDA never approved Estratest for its marketed use.
Do not change medications without first consulting your doctor.
Defendant Details
| Name (Stock Symbol) | Brief Description |
|---|---|
| Solvay Pharmaceuticals | Solvay Pharmaceuticals, Inc. and its wholly owned subsidiary Unimed Pharmaceuticals, Inc., are part of Solvay S.A., a Belgium-based chemical and pharmaceutical company. |